Jane Street’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Jane Street’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-48,238	Closed	-$76.7K	–	10484
2024 Q1	$76.7K	Sell	48,238 -10,742	-18%	-$15.9K	﹤0.01%	8629
2023 Q4	$50.7K	Sell	58,980 -11,966	-17%	-$10.5K	﹤0.01%	8774
2023 Q3	$75.9K	Buy	70,946 +31,413	+79%	+$65K	﹤0.01%	8046
2023 Q2	$102K	Sell	39,533 -25,785	-39%	-$92K	﹤0.01%	7991
2023 Q1	$266K	Buy	65,318 +33,594	+106%	+$155K	﹤0.01%	7385
2022 Q4	$159K	Buy	+31,724	New	+$199K	﹤0.01%	7830
2021 Q1	–	Sell	-7,066	Closed	-$214K	–	9716
2020 Q4	$214K	Buy	+7,066	New	+$155K	﹤0.01%	6873

Jane Street's NGM Position: Q2 2024 in Review

Jane Street sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 48,238 shares — an estimated $76.7K sold.

Jane Street first reported a position in NGM in Q4 2020 and held it in 7 quarters. The position peaked at $266K in Q1 2023. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

Jane Street reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Jane Street sold 48,238 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $76.7K.
Jane Street first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Jane Street's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $266K in Q1 2023.
0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Jane Street's 13F filing for Q2 2024, filed 15 Aug 2024.